Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
01177 SINO BIOPHARM
RTNominal up3.020 +0.010 (+0.332%)
Research Report

17/01/2020 11:56

{I-bank focus}Jefferies trims Sino Biopharm (01177) to HK$10

[ET Net News Agency, 17 January 2020] Jefferies Research trimmed its target price for
Sino Biopharmaceutical (01177) to HK$10 from HK$13 and maintained its "buy" rating.
The research house has little doubt that Sino Biopharm has one of the best R&D platforms
and pipelines in China. The continuous launch of new products should be able to propel the
growth of the company.
However, in 2020 the nationwide implementation of centralized procurement may hurt the
growth of core products. Though management remains optimistic, Jefferies would rather err
on the side of caution and wait for clearer signals, especially given its high valuation.
Jefferies expects total revenue growth to drop to 5.1% in 2020, due mainly to the impact
of centralized procurement. Core net profit will only grow by 8.4% as a result. (KL)

Remark: Real time quote last updated: 28/03/2024 17:37
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.